<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>Trade Brains Features</provider_name><provider_url>https://tradebrains.in/features</provider_url><author_name>PTI News</author_name><author_url>https://tradebrains.in/features/author/ptinews/</author_url><title>Zydus Lifesciences gets USFDA nod to market generic version of colestipol hydrochloride tablets</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="XAe9DwtArE"&gt;&lt;a href="https://tradebrains.in/features/biz-zydus-lifesciences-usfda/"&gt;Zydus Lifesciences gets USFDA nod to market generic version of colestipol hydrochloride tablets&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://tradebrains.in/features/biz-zydus-lifesciences-usfda/embed/#?secret=XAe9DwtArE" width="600" height="338" title="&#x201C;Zydus Lifesciences gets USFDA nod to market generic version of colestipol hydrochloride tablets&#x201D; &#x2014; Trade Brains Features" data-secret="XAe9DwtArE" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script type="text/javascript"&gt;
/* &lt;![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
/* ]]&gt; */
&lt;/script&gt;
</html><description>New Delhi, Mar 14 (PTI) Zydus Lifesciences Ltd on Monday said it has received the final approval from the US health regulator to market its generic version of colestipol hydrochloride tablets, which is used to lower cholesterol. The approval by the US Food and Drug Administration is for colestipol hydrochloride of 1 mg strength, the [&hellip;]</description></oembed>
